The ␤-amyloid protein (A␤), the major component of the senile plaques found in Alzheimer brains, derives from a larger ␤-amyloid precursor protein (APP). Alternative splicing of the APP gene yields three major APP messenger RNAs (mRNAs), which, in turn, give rise to the APP 770 , APP 751 , and APP 695 protein isoforms. In this study we examined the effects of thyroid hormone on APP expression in N2a-␤ neuroblastoma cells. T 3 caused a significant increase in the APP 770 mRNA band, in detriment of the APP 695 mRNA, which was proportionately reduced. In agreement with these results, T 3 markedly altered the relative ratio of intracellular APP isoforms, increasing the amount of APP 770 and causing an equivalent reduction of the immature APP 695 isoform. In accordance with these results, the soluble APP 695 -derived form was specifically reduced in the culture medium obtained from T 3 -treated cells. In contrast, the increase in intracellular APP 770 was not followed by an enhanced release of soluble derivatives of this isoform. These results suggest that T 3 regulates not only APP gene splicing, but also the processing and secretion of the APP peptides. According to our results, thyroid hormone might play a role in the development of Alzheimer's disease by modulating the intracellular and extracellular contents of APP isoforms. (Endocrinology 139: [2692][2693][2694][2695][2696][2697][2698] 1998) 
A LZHEIMER'S disease is a degenerative disorder of the central nervous system that causes mental deterioration and progressive dementia and is accompanied by neuropathological lesions, including the presence of senile plaques, of which the ␤-amyloid protein (A␤), a hydrophobic 39-to 43-residue amino acid peptide, is the major component (1, 2) . As illustrated in Fig. 1 , the ␤-amyloid protein is proteolytically derived from a set of alternatively spliced ␤-amyloid precursor proteins (APP) that are encoded by a single gene located on human chromosome 21 (3) . Expression of APP plays a central role in Alzheimer's disease, and it has been suggested that an increase in the production of this protein might actively contribute to the development of this pathology (4 -6) . The APP gene is expressed in virtually all mammalian tissues and gives rise to three major APP messenger RNAs (mRNAs) that encode for the isoforms APP 695 , APP 751 , and APP 770 , all of them containing the ␤-amyloid peptide sequence. In addition, the 751 and 770 isoforms contain a 56-amino acid Kunitz-type protease inhibitor domain. The APP isoforms are membrane glycoproteins that are proteolytically cleaved by the action of a set of enzymes referred to generically as secretases (Fig. 1) . The ␣-secretase cleaves the protein between the residues Lys 16 and Leu 17 of the A␤ domain, precluding the generation of amyloidogenic fragments (7, 8) . Proteolytic cleavage of APP by ␣-secretase results in the release of soluble full-length amino-terminal fragments (sAPP), which appear to be involved in neurotropic events, such as neuronal development or neurite extension (9) . In contrast, the synthesis and release of amyloidogenic fragments require the successive action of the ␤-secretase, which cleaves the precursor at the amino-terminus of the A␤ sequence, and the ␥-secretase, which, in turn, cuts at positions 39 -43 of this domain (10 -12) . APP processing can be regulated by a variety of compounds in a cell-dependent manner. Activation of the protein kinase C or protein kinase A signal transduction pathways specifically stimulates secretory nonamyloidogenic processing, thus increasing the release of soluble fragments of APP (13) (14) (15) (16) . A similar effect is induced by 17␤-estradiol, a ligand of the steroid/thyroid hormone superfamily of nuclear receptors, in a human breast carcinoma cell line (17) . In contrast, overexpression of APP has been shown to induce the activity of the alternative processing that generates the ␤-amyloid peptide (18) .
The antiprotease activity associated with Kunitz-containing APP peptides might locally affect its own processing. Therefore, the relative ratio of Kunitz (770 and 751) to nonKunitz (695) isoforms may also play a role in Alzheimer's disease. In this respect, different factors, including retinoic acid, another ligand of the nuclear receptor superfamily, can specifically alter APP pre-mRNA splicing (19 -22) and APP processing (16, 23, 24) in a variety of cell types.
An apparent relationship between thyroid status and Alzheimer's disease has been suggested. Hypothyroidism is accompanied by neurological symptoms that might, in a way, resemble those observed in Alzheimer's disease. Moreover, and although a strong link between thyroid hormones and Alzheimer's disease has not been yet established, it has been suggested that a history of thyroid dysfunction might represents a risk factor for that pathology (25, 26) . In addition, thyroid hormones normally exert their action by binding to nuclear receptors, and a reduction of thyroid hormone receptor mRNA levels in Alzheimer hippocampal cells has been described (27) .
In the present study, we examined the effects of T 3 on the splicing and secretion of APP in N2a-␤ neuroblastoma cells, a stably transfected subline of N2a cells that expresses the ␤1 isoform of thyroid hormone receptor. Our results show that T 3 affects not only the splicing but also the secretion of APP in neuroblastoma cells.
Materials and Methods

Chemicals and antibodies
DMEM and FCS were purchased from BioWhittaker (Verviers, Belgium). Resin AG1X8 was obtained from Bio-Rad (Richmond, CA). Polyclonal antibody 369A against the cytoplasmic domain of APP (23) was a gift from Dr. Samuel E. Gandy (Cornell University Medical Center, New York, NY). The polyclonal antibody R7, recognizing the Kunitz APP region (28) , was a gift from Dr. N. Robakis (Mount Sinai School of Medicine, New York, NY). The monoclonal antibody 22C11, which recognizes the amino-terminus of APP, was purchased from Boehringer Mannheim (Mannheim, Germany), and the 6E10 and 4G8 monoclonal antibodies raised against the ␤-amyloid peptide were obtained from Senetek (Maryland Heights, MO). The epitopes recognized by the different antibodies are depicted at the top of Fig. 1 . The second biotinylated antirabbit antibody and the peroxidase-conjugated streptavidin used in Western blot analysis were purchased from Amersham International (Aylesbury, UK). Reverse transcriptase and other reagents used for the PCR analysis of DNA were obtained from Promega (Madison, WI).
Cell culture
Murine N2a-␤ neuroblastoma cells, a gift from Dr. Dussault (29) , were cultured in DMEM supplemented with 10% FCS depleted of thyroid hormones by treatment with resin AG1X8, as previously described (30) . Previous to the experiments, cells were plated in 90-mm diameter culture tissue dishes (Falcon, Becton Dickinson, Plymouth, UK), and 24 -48 h later were incubated in the absence or presence of T 3 . At the times indicated in the text, media and cells were collected and stored frozen until posterior analysis. Parental N2a cells were grown in medium containing 10% FCS as described by Ortiz-Caro et al. (31) , but the experiments were carried out in the medium containing thyroid hormonedepleted serum.
Western blot analysis
Cellular proteins were extracted by lysis with a buffer [150 mm NaCl, 50 mm Tris (pH 8), 2 mm EDTA, 1% Triton, and 0.1% SDS] containing the protease inhibitors phenylmethylsulfonylfluoride (1 mm) and leupeptin (10 g/ml). The protein content of cells was determined by using the BCA assay (Pierce, Rockford, IL), according to the manufacturer's instructions. Equal amounts (40 g) of cell extracts were then electrophoresed in an 8% SDS-polyacrylamide gel and transferred to an Immobilon polyvinylidine difluoride membrane. Nonspecific binding was blocked with 5% nonfat dried milk in Tris-buffered saline and 0.1% Tween-20 for 2-3 h at room temperature, and cellular APP was detected with a 1:1500 dilution of the rabbit polyclonal antibody 369A, raised against the carboxyl-terminal domain of human APP, or with the same dilution of the polyclonal antibody R7, which specifically recognizes the Kunitz-containing isoforms of APP. After 1-h incubation at room temperature, the membrane was washed and incubated with a second biotinylated antirabbit antibody (1:2000) for an additional hour, washed again, and finally incubated for 1 h with 1:2000 peroxidase-conjugated streptavidin. All incubations took place at room temperature, and detection by enhanced chemiluminiscence (ECL, Amersham International) was carried out according to manufacturer's indications. The monoclonal antibody 6E10, which specifically recognizes the A␤-containing APP isoforms, was used at a final concentration of 1.5 l/ml.
Secreted full-length APP isoforms were detected by the same method from 50 l (1:100 from total) of conditioned medium using monoclonal antibody 22C11 at a final concentration of 10 g/ml. A minimal variation of the method was introduced to detect the 4-kDa ␤-amyloid peptide in the culture medium. In this case, 50-to 100-l aliquots of medium were electrophoresed in a 16.5% Tris-tricine gel, and the peptide was analyzed with different dilutions (0.1-1.5 l/ml) of anti-A␤ monoclonal antibodies 6E10 and 4G8.
The apparent molecular mass (kilodaltons) of the detected bands was always determined using a wide range protein standard (Mark 12 from NOVEX, San Diego. CA). The intensity of the bands was quantified by densitometric scan of the autoradiograms, and the results for a particular isoform are expressed as a percentage of the total APP, either cellular or soluble.
RT-PCR amplification of mRNA
RT-PCR was used to analyze the differential expression of APP mRNA isoforms. Two oligonucleotides that flanked exons 6 and 9 of the APP gene were used. The forward primer was 5Ј-TGAAGACAAAG-TAGTAGAAGT-3Ј, and the reverse primer was 5Ј-ACCTGGGACAT-TCTCTCTCGGTGCTTGGC-3Ј. Total RNA was extracted from cell cultures by the guanidine thiocyanate method (32) , and first strand complementary DNA (cDNA) synthesis was performed on 5-6 g RNA using 20 U AMV reverse transcriptase and 100 ng reverse primer. The PCR reaction was set up using the cDNA previously obtained in a standard 100-l buffer containing 5 U Taq polymerase and 100 ng of the appropriate primers. These primers were chosen to generate fragments of 562, 505, and 337 bp corresponding to the three major mRNA isoforms. Samples were subjected to 25-30 cycles of amplification (denaturation at 94 C for 1 min, annealing at 55 C for 1 min, and extension at 72 C for 2 min). PCR products were analyzed on 3% NuSieve-GTG agarose and visualized by ethidium bromide staining.
Statistics
Unless indicated otherwise, all data points are the mean of at least duplicate cultures that did not normally vary by more than 10 -15% or are the mean Ϯ sem of the results obtained in at least three separate experiments performed in duplicate. The significance of differences was calculated with Student's test.
Results
Effects of T 3 on the cell-associated APP protein
Cellular APP isoforms were detected from cell lysates by Western blot using antibody 369A. As illustrated in Fig. 2A , 5 nm T 3 induced a significant change in the pattern of intracellular APP species, mainly affecting the 95-and 125-kDa bands. Based upon earlier reports (23, 24, 33) , the smallest 95-kDa band could represent the immature APP 695 isoform, whereas the lowest mobility bands more likely represent the mature Kunitz-containing APP 770 and APP 751 species. According to this, T 3 consistently induces a reduction of immature APP 695 as well as an increase in the mature APP 770 form after 24 -48 h of treatment. In addition, the intermediate bands do not appear to be affected by the thyroid hormone. However, a complete definition of those intermediate bands has not been possible, and a specific modification of one of those species cannot be definitely discarded. Figure 2B illustrates the densitometric quantitation of the different bands at 48 h of treatment. The intensity of the 95-kDa band, which represents the immature APP 695 isoform, was reduced to less than 50% of the control value, whereas the 125-kDa band (APP 770 ) was increased by more than 2-fold in the cells after T 3 treatment. As indicated above, the bands from 105-118 kDa, which were considered a unique species in the densitometric analysis, were not affected by T 3 . No effects were detected either in N2a-␤ cells before 12 h of T 3 treatment or in parental N2a cells, in which the nuclear T 3 receptor is expressed at very low concentrations, at any of the time periods analyzed (data not shown).
The effect of T 3 on the APP 770 isoform was confirmed in two separate experiments performed with the R-7 antibody, which specifically recognizes the Kunitz-containing APP isoforms (28) . Identical results were obtained in both experiments. As illustrated in Fig. 3 , thyroid hormone induces a specific increase in the slowest mobility band, which corresponds to the APP 770 isoform. The effect was observed after 24 -48 h of treatment with 0.1 or 5 nm T 3 , although the increase was less marked with the lowest hormone concentration. As expected, the results were essentially identical to those observed using the 369A antibody, and the Kunitzcontaining APP 770 was increased by approximately 2-fold in N2a-␤ cells incubated in the presence of 5 nm T 3 for 48 h. Antibody 369A can also recognize different isoforms of APLP, an amyloid precursor-like protein that is identical to APP except for the lack of the A␤ sequence. One of these isoforms, which contains 695 residues (APLP 695 ), might run together with APP 695 . Cultured neuronal cells normally express very low levels of APLP 695 (34) , and it is unlikely that this isoform could interfere and mask the effect of T 3 on APP in N2a-␤ cells. However, to definitely establish the identity and regulation of APP 695 , we performed additional experiments using monoclonal antibody 6E10, which specifically recognizes APP, but not APLP, isoforms. As shown in Fig.  4A , antibody 6E10 detects a band identical to the 95-kDa species observed with the 369A antibody. As illustrated in Fig. 4B , the regulation of this band is also identical to that obtained with antibody 369A. These results confirm those presented in Fig. 2 , and although we cannot discard a possible contribution of APLP forms to the species detected with the antibody 369A, it can be concluded that T 3 specifically decreases the cellular content of APP 695 .
Influence of T 3 on the accumulation of APP secreted forms into the culture medium
The full-length soluble derivatives of APP released into the culture medium were analyzed with monoclonal antibody 22C11. A similar pattern of bands was observed at the two time points studied, 24 and 48 h. As shown in Fig. 5 , incubation of cells with 5 nm T 3 resulted in a significant and specific reduction of the 93-kDa band, which represents the sAPP 695 species accumulated in the medium. As observed in Fig. 5B , the intensity of the 93-kDa band was reduced to approximately 50% of the control value after 48 h of incubation with T 3 . As occurred with the cell-associated APPs, these effects were not observed in the parental N2a cell line. However, and contrary to the effect observed on the intracellular pattern of proteins, no significant differences in the intensity of the soluble Kunitz-containing bands were observed at 24 or 48 h between the T 3 and control groups. Taken together, these results suggest that thyroid hormones may selectively affect not only the processing but also the release of APP.
Effects of T 3 on APP mRNA isoforms
To examine whether the specific changes induced by T 3 on the cellular APP isoforms were the result of changes in the alternative splicing of the APP mRNA precursor, we analyzed the relative ratios of the different mRNA isoforms by RT-PCR. The alternative splicing pattern of exons 7 and 8 was studied using primers that amplify sequences between exons 6 and 9. Three major bands were detected at the expected positions of 562 bp (APP 770 ), 505 bp (APP 751 ), and 337 bp (APP 695 ). Figure 6 illustrates the results obtained in a representative experiment in which the cDNA was amplified through 30 cycles. Similar results were obtained in an addi- tional experiment performed under the same conditions and in two separate experiments performed with only 25 cycles. Although under our conditions the RT-PCR analysis is not quantitative, the relative abundance of bands was essentially identical after 25 or 30 cycles, thus indicating that in that phase the intensity of bands is proportional to the initial concentration of the corresponding isoforms.
As shown in Fig. 6 , incubation of cells for 48 h with 5 nm T 3 significantly altered the splicing pattern, decreasing the content of APP 695 in favor of the APP 770 form. Thus, T 3 treatment led to a pattern of isoforms that, to some extent, resembled that in nonneuronal cells. The effect was not yet evident at 24 h of incubation (data not shown), but it was maintained after 72 h of treatment.
Discussion
Expression and metabolism of APP play a central role in the development of Alzheimer's disease. It has been previously described that ligands of nuclear receptors, such as 17␤-estradiol or retinoic acid, the active metabolite of vitamin A, are involved in the splicing and/or processing of APP (17, 20 -22) . In this study, we have demonstrated that T 3 , another ligand of the nuclear receptor superfamily, could also play an important role in the regulation of these processes.
T 3 , the more active form of the thyroid hormones, specifically alters APP gene splicing in N2a-␤ neuroblastoma cells, decreasing the relative amount of APP 695 mRNA in favor of APP 770 mRNA, which encodes a Kunitz-containing form. The changes induced by T 3 give rise to a pattern of APP mRNA that, to some extent, resembles that of peripheral and nonneuronal cells.
The precise mechanism(s) involved in the regulation of APP by this hormone remains unclear. However, the lack of effect of T 3 on APP expression in the parental N2a cell line, which expresses very low levels of hormone receptor (31) , strongly suggests a receptor-mediated mechanism. The effects induced by the thyroid hormone on the pattern of APP mRNA isoforms could be secondary to the regulation of specific factors involved in the alternative splicing of the gene. In this respect, thyroid hormone as well as retinoic acid can regulate the expression of SmN, a specific splicing protein that is only expressed in adult heart and brain (35) . Although the precise function of this protein remains unclear, this finding suggests a potential role of this or another yet unidentified splicing factor in the response of neuronal cells to thyroid hormones.
T 3 alters the intracellular pattern of the APP isoforms, leading to a significant reduction of the immature nonKunitz APP 695 isoform and an increase in the Kunitz-containing mature forms. This pattern of intracellular proteins shows a good correlation with the T 3 -induced distribution of APP mRNA isoforms and is probably the direct result of the alternative mRNA splicing. In contrast, the parallelism between the mRNA and cellular holoprotein patterns could not be extended to the T 3 -induced changes in the sAPP isoforms released to the culture medium. Treatment of N2a-␤ cells with T 3 leads to a diminished accumulation of sAPP 695 , but not to an increase in other soluble isoforms.
Additionally, efforts have been made to detect the amyloid peptide in the medium. Unfortunately, the levels of A␤ produced from endogenous APP in N2a-␤ cells are extremely low, and this precludes a reliable observation of the peptide.
As the pattern of released forms in the T 3 -treated cells did not correlate with the pattern of cellular APP, it might be speculated that T 3 can regulate the synthesis and/or activity of some protease(s) involved in the metabolism of this precursor. In this respect, it has been reported that tacrine, a drug extensively used for the treatment of Alzheimer's disease, effectively reduces the secretion of soluble APP derivatives by a mechanism that probably involves inhibition of an acetylcholinesterase-associated proteolytic activity (36) .
As the effects of tacrine in human neuroblastoma IMR-32 cells in part resemble those elicited by T 3 in N2a-␤ cells, a similar mechanism might be proposed. However, the differential effect exerted by T 3 on the secretion of soluble APP 695 and APP 770/751 into the culture medium suggests a more complex mechanism involving additional effects of the thyroid hormones in the regulation of sAPP secretion. Further experiments will be necessary to clarify the mechanisms by which thyroid hormones regulate the processing and release of APP isoforms. The relevance of our results for the management of Alzheimer's patients is still unclear at present. On the one hand, it has been reported that isoforms containing the Kunitz protease inhibitor domain are preferentially expressed in the Alzheimer brain (37) , whereas the 695 form is reduced (4) . According to these descriptions, the thyroid hormones should be considered a risk factor because they induce a pattern of APP in which the Kunitz-containing forms are preferentially expressed. On the other hand, it has been suggested that deposition of ␤-amyloid in senile plaques may be mainly derived from APP 695 . In agreement with these reports, thyroid hormones might protect against the amyloid deposition by decreasing the presence of APP 695 and its soluble derivative sAPP isoform into the cells and the extracellular space, respectively.
It is evident that new experiments should be performed to fully understand the role of thyroid hormone in Alzheimer's disease. However, the results described in the present work support the idea that thyroid hormones might play a role in this pathology by modulating the cellular and extracellular content of APP transcripts through a mechanism that probably involves binding to the nuclear receptor and expression of genes that encode different splicing factors that must be identified in future studies. In addition, and as T 3 receptor mRNA levels are decreased in Alzheimer hippocampal cells (27) , the cellular sensitivity to T 3 might be affected in Alzheimer's disease.
